Tailoring the management of localised colon cancer to the Asian population
Risk assessment and alternative fluoropyrimidine regimens are the main changes in the Pan-Asian adapted ESMO Clinical Practice Guidelines, reinforcing ESMO’s commitment in the region
IMpower010 and DESTINY-Lung01 are likely to change clinical practice in Asia
However, regulatory and financial issues will shape when and where this happens
What is the impact of first-line nivolumab on subsequent therapy choices for metastatic gastric cancer?
Knock-on effects of early immune checkpoint inhibitor use stimulate consideration of alternative approaches for further treatment lines
Some practice-changing results in breast cancer are perceived differently in low-resourced countries
Cost, limited drug availability and lack of diagnostic testing facilities are hurdles to adopting practice-changing recommendations in some Asian countries
New insights into the mechanism of acquired resistance to KRAS G12C inhibitors
Sequencing data suggest that non-G12C KRAS mutations could mediate intrinsic resistance to treatments in non-small-cell lung cancer, but functional confirmation is required
Study sheds light on lung adenocarcinoma-to-squamous transdifferentiation mechanism
AKT and EZH2 are identified as potential therapeutic targets to limit acquired resistance to osimertinib in patients with EGFR-mutated tumours of the lung
Next-generation sequencing of circulating tumour DNA can optimise clinical trial recruitment
Molecular pre-screening identified targetable alterations in patients with unknown genomic drivers
Pathogenic germline variants are more common than ‘incidental’
Tumour-only molecular profiling can spot hereditary cancer syndromes but resources are critical to make the most of this piece of information
How can exosome research improve patient management?
As the literature on exosomes continues to grow in cancer basic science, important questions remain regarding opportunities in the clinic
Healthcare budgets are still a main hurdle to global use of molecular testing for precision oncology
Inequities in access to targeted cancer treatments are due to the high costs of tests, limited number of approved medicines or clinical trials and poor communication with patients, as two new surveys report